Improving immune responses to cancer treatment by targeting the epigenome
Targeting the Epigenome to Improve Responses to Immunotherapy
This study is looking at how to boost the immune system's ability to fight breast cancer by blocking a protein called TIM-3 on certain immune cells, which could make treatments like chemotherapy and immunotherapy work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11006264 on NIH RePORTER |
What this research studies
This research investigates how certain immune cells, known as conventional dendritic cells (cDCs), can be manipulated to enhance the body's immune response against tumors. The study focuses on a specific protein called TIM-3, which is found on these immune cells in breast cancer models. By blocking TIM-3, the researchers aim to improve the effectiveness of existing cancer treatments, such as chemotherapy and immunotherapy, by altering how immune cells and T cells interact within tumors. Patients may benefit from a better understanding of how to enhance their immune response to cancer therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with breast cancer, particularly those with triple-negative or luminal B subtypes.
Not a fit: Patients with cancers other than breast cancer or those who are not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient outcomes.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses through similar approaches, indicating potential for success in this area.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Gardner, Alycia — Brigham and Women's Hospital
- Study coordinator: Gardner, Alycia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.